The Motley Fool··Jonathan PoncianoSaturn V Capital Exits Ocular Therapeutix as Revenue Disappoints Despite Clinical Promise
Saturn V Capital fully exited Ocular Therapeutix, selling 1.5M shares for $14.34M as Q1 revenue disappointed despite positive clinical trials and $666.7M cash reserves.
OCULbiotechfund exit